By Patrick Hannon, et al, July 10, 2020
In order to better understand the data being reported from the COVID-19 public health emergency that has gripped the world in recent months, it is helpful to understand the mathematical and statistical considerations of binary classification tests. These include COVID-19 antigen tests (patient has the active pathogen in their body) and COVID-19 anti-body tests (patient has been exposed and has mounted an immune response).
Download the whitepaper on “Pharmaceutical Industry Challenges Facing Clinical Trial Disclosure and Transparency.” While global regulatory authorities routinely update clinical trial disclosure and transparency requirements, new regulations set to take effect in 2020 and 2021 will dramatically change how sponsors report clinical trial data.
Each month, MMS shares key stories on the evolution of the pharmaceutical industry. Here is a selection from May, including: FDA Coronavirus (COVID-19) Update, 2019 Avoca State of the Industry Report, PHUSE clinical trial transparency project, and more.
Join us for an Expert Insights Webinar on May 27 titled “Recommended Changes for Pharma Companies in Response to COVID-19”
By Staff Writer, April 30, 2020
Each month, MMS shares key stories on the evolution of the pharmaceutical industry. Here is a selection from April 2020.
By Staff Writer, April 28, 2020
The COVID-19 pandemic has impacted the way many pharmaceutical, biotech, and CRO companies are working, rewarding flexibility and agile resourcing and operating models. In this expert insights blog, we sit down (virtually) with Kelly J. Hill, Executive Director, Global Business Operations and Strategy and Michelle Gayari, Executive Director, Global Operations to learn how MMS operates with safety, urgency, and innovation during this pandemic.
Experts at MMS have reviewed COVID-19 guidance documents and taken into account the current state of clinical research globally to ensure our services align with these new challenges, whether those sponsors be virtual or large firms with treatments for common illnesses or rare conditions. What has been identified in this whitepaper are key areas of change faced by the industry.
by Jessica Alamdari, April 3, 2020
During these unprecedented times, many businesses are struggling to continue business as usual while the world is rapidly changing around them; however, certain businesses continue to thrive. Throughout this COVID-19 pandemic, companies like MMS, among other leaders in the pharmaceutical industry, are not only carrying out typical day-to-day business operations, but they are well-positioned to offer additional support to companies unable to adapt.
by Staff Writer, March 25, 2020
Each month, MMS shares key stories on the evolution of the pharmaceutical industry. Here is a selection from March 2020.
by Staff Writer, March 17, 2020
In this Expert Insights interview, we sit down with Dr. Uma Sharma, Chief Scientific Officer at MMS Holdings. Dr. Sharma discusses her thoughts surrounding the Circle of Concern and the Circle of Influence, including how it influences the culture at MMS.